US7973137B1
(en)
|
1996-03-28 |
2011-07-05 |
Johns Hopkins University |
Cell compositions comprising molecular complexes that modify immune responses
|
DE60138922D1
(en)
*
|
2000-10-10 |
2009-07-16 |
Univ Oklahoma |
COMPARATIVE LIGAND ILLUSTRATION OF MHC-POSITIVE CELLS
|
US7319012B2
(en)
|
2001-05-30 |
2008-01-15 |
Gene Therapy Systems, Inc. |
Protein arrays and methods and systems for producing the same
|
WO2003006632A2
(en)
*
|
2001-07-12 |
2003-01-23 |
Canvac |
Methods and compisitions for activation human t cells in vitro
|
TW200416043A
(en)
*
|
2002-11-07 |
2004-09-01 |
Queensland Inst Med Res |
Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
|
EP1558723A4
(en)
*
|
2002-11-07 |
2006-02-15 |
Johnson & Johnson Res Pty Ltd |
A means of producing and utilising a population of disease specific cytotoxic t-lymphoctyes
|
EP2343083B1
(en)
*
|
2003-06-27 |
2014-01-15 |
International Institute of Cancer Immunology, Inc. |
Method of diagnosing cancer comprising the measurement of WT1-specific CTL precursor cells
|
WO2007105954A1
(en)
*
|
2006-03-16 |
2007-09-20 |
Leiden University Medical Center |
Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes
|
EP2012829A4
(en)
*
|
2006-04-24 |
2010-04-21 |
Protelix Inc |
Method for producing viral vaccine and therapeutic peptide antigens
|
KR101900639B1
(en)
|
2007-03-05 |
2018-09-19 |
인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 |
Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
|
US9695397B2
(en)
*
|
2008-10-01 |
2017-07-04 |
Immunovative Therapies Ltd. |
Th1 vaccination priming for active immunotherapy
|
CA3118108C
(en)
|
2010-11-12 |
2024-02-20 |
Oncour Pharma, Inc. |
Modified immune-modulating particles comprising poly(lactic acid)
|
CN103764826A
(en)
|
2011-06-28 |
2014-04-30 |
株式会社癌免疫研究所 |
Receptor gene for peptide cancer antigen-specific t cell
|
CA2876495C
(en)
|
2012-06-21 |
2023-10-17 |
Northwestern University |
Peptide conjugated particles
|
CN105263476A
(en)
*
|
2013-03-13 |
2016-01-20 |
库尔制药开发公司 |
Immune-modifying particles for the treatment of inflammation
|
ES2782002T3
(en)
|
2013-03-14 |
2020-09-09 |
Univ Johns Hopkins |
Nanoscale Artificial Antigen Presenting Cells
|
SI3033102T2
(en)
|
2013-08-13 |
2024-03-29 |
Northwestern University |
Peptide conjugated particles
|
SG11201608862SA
(en)
|
2014-04-23 |
2016-11-29 |
Juno Therapeutics Inc |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
CN107075483A
(en)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
The engineered cell treated for adoptive cellular
|
TWI805109B
(en)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
Antibodies and chimeric antigen receptors specific for cd19
|
KR20210032011A
(en)
*
|
2014-09-17 |
2021-03-23 |
더 존스 홉킨스 유니버시티 |
Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
|
CN117427091A
(en)
|
2014-10-20 |
2024-01-23 |
朱诺治疗学股份有限公司 |
Compositions and methods for administration in adoptive cell therapy
|
PL3215601T3
(en)
|
2014-11-05 |
2020-11-02 |
Juno Therapeutics, Inc. |
Methods for transduction and cell processing
|
CN107206025A
(en)
|
2014-12-03 |
2017-09-26 |
朱诺治疗学股份有限公司 |
The method and composition treated for adoptive cellular
|
MA41346A
(en)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
POST-TRANSCRIPTIONAL REGULATORY ELEMENTS OF MODIFIED HEPATITIS
|
TWI718118B
(en)
|
2015-01-16 |
2021-02-11 |
美商奇諾治療有限公司 |
Antibodies and chimeric antigen receptors specific for ror1
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
CN108174607A
(en)
|
2015-05-29 |
2018-06-15 |
朱诺治疗学股份有限公司 |
For adjusting the composition and method of inhibition interaction in genetically engineered cell
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
ES2768957T3
(en)
|
2015-09-24 |
2020-06-24 |
Abvitro Llc |
HIV Antibody Compositions and Methods of Use
|
US10928392B2
(en)
|
2015-09-25 |
2021-02-23 |
Abvitro Llc |
High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
|
CA3002742A1
(en)
|
2015-10-22 |
2017-04-27 |
Juno Therapeutics Gmbh |
Methods, kits, agents and apparatuses for transduction
|
MA45488A
(en)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
CELL CULTURE PROCESSES, KITS AND APPARATUS
|
MA45489A
(en)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
MA44314A
(en)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS
|
US11819516B2
(en)
|
2015-11-06 |
2023-11-21 |
The Regents Of The University Of Michigan |
Immunotherapy
|
US20180355014A1
(en)
|
2015-12-03 |
2018-12-13 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
WO2017096327A2
(en)
|
2015-12-03 |
2017-06-08 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against cell therapies
|
ES2901795T3
(en)
|
2015-12-04 |
2022-03-23 |
Juno Therapeutics Inc |
Methods and compositions related to toxicity associated with cell therapy
|
US20190365656A1
(en)
*
|
2016-01-04 |
2019-12-05 |
Cour Pharmaceuticals Development Company, Inc. |
Particles encapsulating fusion proteins containing linked epitopes
|
MA43758A
(en)
|
2016-03-16 |
2018-11-28 |
Yuan Ji |
METHODS FOR DETERMINING THE DOSAGE OF A THERAPEUTIC AGENT AND RELATED TREATMENTS
|
US20190355459A1
(en)
|
2016-03-16 |
2019-11-21 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
KR20190021200A
(en)
|
2016-03-22 |
2019-03-05 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
Early intervention to prevent or reduce toxicity
|
IL302641A
(en)
|
2016-05-06 |
2023-07-01 |
Juno Therapeutics Inc |
Genetically Engineered Cells and Methods of Making the Same
|
ES2901215T3
(en)
|
2016-05-27 |
2022-03-21 |
Aadigen Llc |
Peptides and nanoparticles for intracellular delivery of genome editing molecules
|
MX2018014991A
(en)
|
2016-06-03 |
2019-08-29 |
Memorial Sloan Kettering Cancer Center |
Adoptive cell therapies as early treatment options.
|
MA45341A
(en)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
METHODS FOR TREATING B-LYMPHOCYTE MALIGNITIES USING ADOPTIVE CELL THERAPY
|
MA45491A
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
|
EP3475446A1
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
KR102553195B1
(en)
|
2016-07-29 |
2023-07-07 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Anti-idiotypic antibodies to anti-CD19 antibodies
|
US11421287B2
(en)
|
2016-07-29 |
2022-08-23 |
Juno Therapeutics, Inc. |
Methods for assessing the presence or absence of replication competent virus
|
JP7295795B2
(en)
|
2016-07-29 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
Immunomodulatory Polypeptides and Related Compositions and Methods
|
US20190211292A1
(en)
|
2016-09-12 |
2019-07-11 |
Juno Therapeutics, Inc. |
Perfusion bioreactor bag assemblies
|
CA3038897A1
(en)
|
2016-09-28 |
2018-04-05 |
Atossa Genetics Inc. |
Methods of adoptive cell therapy
|
CA3037086A1
(en)
|
2016-10-03 |
2018-04-12 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
CN110381963A
(en)
|
2016-10-13 |
2019-10-25 |
朱诺治疗学股份有限公司 |
It is related to the immunotherapy method and composition of tryptophan metabolic pathway regulator
|
WO2018093591A1
(en)
|
2016-11-03 |
2018-05-24 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
MA46783A
(en)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
T-CELL THERAPY AND BTK INHIBITOR POLYTHERAPY
|
MX2019006286A
(en)
|
2016-12-03 |
2020-02-07 |
Juno Therapeutics Inc |
Methods for determining car-t cells dosing.
|
JP2020511462A
(en)
|
2016-12-03 |
2020-04-16 |
ジュノー セラピューティクス インコーポレイテッド |
Methods and compositions for using therapeutic T cells in combination with kinase inhibitors
|
AU2017368332A1
(en)
|
2016-12-03 |
2019-06-13 |
Juno Therapeutics, Inc. |
Methods for modulation of CAR-T cells
|
KR20190098747A
(en)
|
2016-12-05 |
2019-08-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Method of manufacturing engineered cells for adoptive cell therapy
|
EP3568414A1
(en)
|
2017-01-10 |
2019-11-20 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
JP2020505034A
(en)
|
2017-01-20 |
2020-02-20 |
ジュノ セラピューティクス ゲーエムベーハー |
Cell surface conjugates and related cell compositions and methods
|
EP4269594A3
(en)
|
2017-02-17 |
2023-12-20 |
Fred Hutchinson Cancer Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
JP7228522B2
(en)
|
2017-02-27 |
2023-02-24 |
ジュノー セラピューティクス インコーポレイテッド |
Compositions, articles of manufacture, and methods for dosing in cell therapy
|
WO2018170188A2
(en)
|
2017-03-14 |
2018-09-20 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
EP3607319A1
(en)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
MA54103A
(en)
|
2017-04-14 |
2021-09-15 |
Juno Therapeutics Inc |
METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION
|
WO2018195175A1
(en)
|
2017-04-18 |
2018-10-25 |
FUJIFILM Cellular Dynamics, Inc. |
Antigen-specific immune effector cells
|
JP7339160B2
(en)
|
2017-04-27 |
2023-09-05 |
ジュノ セラピューティクス ゲーエムベーハー |
Oligomeric particle reagents and methods of use thereof
|
PT3618842T
(en)
|
2017-05-01 |
2024-01-12 |
Juno Therapeutics Inc |
Combination of a cell therapy and an immunomodulatory compound
|
US11740231B2
(en)
|
2017-06-02 |
2023-08-29 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
EP3630132A1
(en)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
WO2018234370A1
(en)
|
2017-06-20 |
2018-12-27 |
Institut Curie |
Immune cells defective for suv39h1
|
CN111373260A
(en)
|
2017-06-22 |
2020-07-03 |
得克萨斯大学体系董事会 |
Method for producing regulatory immune cells and uses thereof
|
US20220225597A1
(en)
|
2017-06-29 |
2022-07-21 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
KR20200064060A
(en)
|
2017-07-29 |
2020-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Reagent for cell amplification expressing a recombinant receptor
|
AU2018313952A1
(en)
|
2017-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
MX2020001490A
(en)
|
2017-08-09 |
2020-08-06 |
Juno Therapeutics Inc |
Methods for producing genetically engineered cell compositions and related compositions.
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
Gene expression and assessment of risk of developing toxicity following cell therapy
|
US20200292526A1
(en)
|
2017-09-07 |
2020-09-17 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
CN109517820B
(en)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
gRNA of target HPK1 and HPK1 gene editing method
|
SG11202002728VA
(en)
|
2017-10-03 |
2020-04-29 |
Juno Therapeutics Inc |
Hpv-specific binding molecules
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
CA3080509A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
AU2018358250A1
(en)
|
2017-11-01 |
2020-05-14 |
Editas Medicine, Inc. |
Methods, compositions and components for CRISPR-CAS9 editing of TGFBR2 in T cells for immunotherapy
|
EP3703750A1
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
|
CA3084514A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
KR20200074997A
(en)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigens
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
JP2021502077A
(en)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン,インコーポレイテッド |
Methods, compositions and components for CRISPR-CAS9 editing of CBLB on T cells for immunotherapy
|
BR112020008812A2
(en)
|
2017-11-06 |
2020-10-27 |
Juno Therapeutics Inc |
combination of cell therapy and a gamma secretase inhibitor
|
WO2019094835A1
(en)
|
2017-11-10 |
2019-05-16 |
Juno Therapeutics, Inc. |
Closed-system cryogenic vessels
|
MA51210A
(en)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
METHODS FOR DOSING AND MODULATING GENETICALLY MODIFIED CELLS
|
JP2021505168A
(en)
|
2017-12-08 |
2021-02-18 |
ジュノー セラピューティクス インコーポレイテッド |
Methods for Producing Manipulated T Cell Compositions
|
AU2018379094A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
MA51105A
(en)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics Inc |
FORMULATION OF SERUM-FREE MEDIA FOR CELL CULTURE AND METHODS OF USE
|
KR20200110745A
(en)
|
2017-12-15 |
2020-09-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Anti-CCT5 binding molecule and method of use thereof
|
US11919937B2
(en)
|
2018-01-09 |
2024-03-05 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
US11535903B2
(en)
|
2018-01-31 |
2022-12-27 |
Juno Therapeutics, Inc. |
Methods and reagents for assessing the presence or absence of replication competent virus
|
WO2019152743A1
(en)
|
2018-01-31 |
2019-08-08 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
KR20210029707A
(en)
|
2018-04-05 |
2021-03-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Method for producing cells expressing recombinant receptors and related compositions
|
CN112566698A
(en)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T cell receptor and engineered cells expressing the same
|
KR20210044736A
(en)
|
2018-05-03 |
2021-04-23 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Combination therapy of chimeric antigen receptor (CAR) T cell therapy and kinase inhibitor
|
EP3833742A2
(en)
|
2018-08-09 |
2021-06-16 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
KR20210059715A
(en)
|
2018-08-09 |
2021-05-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Integrated nucleic acid evaluation method
|
BR112021003830A2
(en)
|
2018-08-28 |
2021-07-20 |
Fred Hutchinson Cancer Research Center |
methods and compositions for adoptive cell therapy incorporating notch induced signaling
|
SG11202102108QA
(en)
|
2018-09-11 |
2021-04-29 |
Juno Therapeutics Inc |
Methods for mass spectrometry analysis of engineered cell compositions
|
JP2022512872A
(en)
|
2018-10-31 |
2022-02-07 |
ジュノ セラピューティクス ゲーエムベーハー |
Methods for cell selection and stimulation and equipment for them
|
WO2020092848A2
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
WO2020097132A1
(en)
|
2018-11-06 |
2020-05-14 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
US20220008477A1
(en)
|
2018-11-08 |
2022-01-13 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
MX2021005372A
(en)
|
2018-11-08 |
2021-09-14 |
Neximmune Inc |
T cell compositions with improved phenotypic properties.
|
KR20210104713A
(en)
|
2018-11-16 |
2021-08-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Engineered T-cell dosing methods for treatment of B-cell malignancies
|
CN113286813A
(en)
|
2018-11-19 |
2021-08-20 |
得克萨斯大学体系董事会 |
Modular polycistronic vectors for CAR and TCR transduction
|
CN113272427A
(en)
|
2018-11-28 |
2021-08-17 |
得克萨斯大学体系董事会 |
Multiple genome editing of immune cells to enhance functionality and resistance to suppressive environments
|
KR20210096648A
(en)
|
2018-11-29 |
2021-08-05 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Methods and uses thereof for ex vivo expansion of natural killer cells
|
JP2022513685A
(en)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
Methods for Treatment with Adoptive Cell Therapy
|
CN113692285A
(en)
|
2018-11-30 |
2021-11-23 |
朱诺治疗学股份有限公司 |
Methods of administering and treating B cell malignancies in adoptive cell therapy
|
WO2020120649A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
|
CN113365660A
(en)
|
2019-01-29 |
2021-09-07 |
朱诺治疗学股份有限公司 |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase-like orphan receptor 1(ROR1)
|
MX2021013219A
(en)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods.
|
AU2020265749A1
(en)
|
2019-05-01 |
2022-01-06 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
|
EP3980530A1
(en)
|
2019-06-07 |
2022-04-13 |
Juno Therapeutics, Inc. |
Automated t cell culture
|
CA3142361A1
(en)
|
2019-06-12 |
2020-12-17 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
KR20220042161A
(en)
|
2019-07-23 |
2022-04-04 |
엥스띠뛰 퀴리 |
Immune cells defective in SUV39H1
|
KR20220066892A
(en)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Combination therapy of T cell therapy and Zest homologue 2 enhancer (EH2) inhibitor and related methods
|
CN114600172A
(en)
|
2019-08-30 |
2022-06-07 |
朱诺治疗学股份有限公司 |
Machine learning method for classifying cells
|
AU2020343407A1
(en)
|
2019-09-02 |
2022-03-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immunotherapy targeting tumor neoantigenic peptides
|
CA3153700A1
(en)
|
2019-09-09 |
2021-03-18 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
EP4048304A1
(en)
|
2019-10-22 |
2022-08-31 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
BR112022008023A2
(en)
|
2019-10-30 |
2022-07-12 |
Juno Therapeutics Gmbh |
CELL SELECTION AND/OR STIMULATION DEVICES AND USE METHODS
|
CN114980918A
(en)
|
2019-11-07 |
2022-08-30 |
朱诺治疗学股份有限公司 |
Combination of T cell therapy with (S) -3- [4- (4-morpholin-4-ylmethyl-benzyloxy) -1-oxo-1, 3-dihydro-isoindol-2-yl ] -piperidine-2, 6-dione
|
KR20220122656A
(en)
|
2019-12-06 |
2022-09-02 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Anti-idiotypic Antibodies and Related Compositions and Methods Against GPDAC5D-Targeting Binding Domain
|
EP4070097A1
(en)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
|
IL293430A
(en)
|
2019-12-06 |
2022-07-01 |
Juno Therapeutics Inc |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
IL294724A
(en)
|
2020-01-24 |
2022-09-01 |
Juno Therapeutics Inc |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
CN115427550A
(en)
|
2020-01-28 |
2022-12-02 |
朱诺治疗学股份有限公司 |
T cell transduction methods
|
IL295384A
(en)
|
2020-02-12 |
2022-10-01 |
Juno Therapeutics Inc |
Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
AU2021219764A1
(en)
|
2020-02-12 |
2022-09-01 |
Juno Therapeutics, Inc. |
BCMA-directed chimeric antigen receptor T cell compositions and methods and uses thereof
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
BR112022020333A2
(en)
|
2020-04-10 |
2022-11-22 |
Juno Therapeutics Inc |
METHODS AND USES RELATED TO CELL THERAPY DESIGNED WITH A CHIMERIC ANTIGEN RECEPTOR THAT TARGETS B CELL MATURATION ANTIGEN
|
US20230212243A1
(en)
|
2020-05-12 |
2023-07-06 |
Institut Curie |
Neoantigenic Epitopes Associated with SF3B1 Mutations
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
WO2021231657A1
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
JP2023526416A
(en)
|
2020-05-21 |
2023-06-21 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
T cell receptor with VGLL1 specificity and methods of use thereof
|
CN116234558A
(en)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
Engineered T cells conditionally expressing recombinant receptors, related polynucleotides and methods
|
US20230303974A1
(en)
|
2020-07-30 |
2023-09-28 |
Institut Curie |
Immune Cells Defective for SOCS1
|
US20230324408A1
(en)
|
2020-08-05 |
2023-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
CA3201499A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
KR20230151513A
(en)
|
2021-01-11 |
2023-11-01 |
사나 바이오테크놀로지, 인크. |
Uses of CD8 Targeting Viral Vectors
|
JP2024509853A
(en)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
Combination of T cell therapy and DGK inhibitor
|
AU2022235060A1
(en)
|
2021-03-11 |
2023-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tumor neoantigenic peptides and uses thereof
|
EP4304634A1
(en)
|
2021-03-11 |
2024-01-17 |
Institut Curie |
Transmembrane neoantigenic peptides
|
EP4304632A2
(en)
|
2021-03-11 |
2024-01-17 |
Mnemo Therapeutics |
Tumor neoantigenic peptides
|
EP4314280A1
(en)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
EP4314814A1
(en)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
JP2024513054A
(en)
|
2021-03-29 |
2024-03-21 |
ジュノー セラピューティクス インコーポレイテッド |
Combination of CAR T cell therapy and immunomodulatory compounds for the treatment of lymphoma
|
IL307262A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
WO2022234009A2
(en)
|
2021-05-06 |
2022-11-10 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
TW202321457A
(en)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
Use of cd4-targeted viral vectors
|
AU2022324040A1
(en)
|
2021-08-04 |
2024-02-22 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
WO2023105000A1
(en)
|
2021-12-09 |
2023-06-15 |
Zygosity Limited |
Vector
|
TW202342757A
(en)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
Modified paramyxoviridae attachment glycoproteins
|
TW202342498A
(en)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
Modified paramyxoviridae fusion glycoproteins
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023139269A1
(en)
|
2022-01-21 |
2023-07-27 |
Mnemo Therapeutics |
Modulation of suv39h1 expression by rnas
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023178348A1
(en)
|
2022-03-18 |
2023-09-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetically engineered t-cell co-receptors and methods of use thereof
|
WO2023180552A1
(en)
|
2022-03-24 |
2023-09-28 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
WO2023196933A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|